Physicochemical Properties
| Molecular Formula | C27H23BRFNO4 |
| Molecular Weight | 524.378230333328 |
| Exact Mass | 523.079 |
| CAS # | 1390654-28-0 |
| Related CAS # | KRN2;248260-75-5 |
| PubChem CID | 71611938 |
| Appearance | Light yellow to yellow solid powder |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Heavy Atom Count | 34 |
| Complexity | 681 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | C(C1C=CC=CC=1F)C1C2=CC=C(OC)C(OC)=C2C=[N+]2CCC3=CC4OCOC=4C=C3C=12.[Br-] |
| InChi Key | UMRLOOJWWLJVCD-UHFFFAOYSA-M |
| InChi Code | InChI=1S/C27H23FNO4.BrH/c1-30-23-8-7-18-20(11-17-5-3-4-6-22(17)28)26-19-13-25-24(32-15-33-25)12-16(19)9-10-29(26)14-21(18)27(23)31-2;/h3-8,12-14H,9-11,15H2,1-2H3;1H/q+1;/p-1 |
| Chemical Name | 21-[(2-fluorophenyl)methyl]-16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene;bromide |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Without interfering with the high-salt-induced production of NFAT5 and its target genes, KRN2 specifically suppresses the expression of pro-inflammatory genes, such as Nos2 and Il6 [1]. KRN2 directly blocks the DNA binding region between NF-κB p65 and its Nfat5 exon 1 upstream site (base pairs -3000 to +1) and dose-dependently suppresses NF-κB p65's binding to Nfat5 promoter 1. exchanges [1]. |
| ln Vivo | AIA, in which innate immune cells predominate, can be successfully inhibited by KRN2 (3 mg/kg, intraperitoneal injection, once day, for two weeks) [1]. In mice, CIA and AIA can be efficiently inhibited by KRN2 (3 mg/kg, intraperitoneal injection, daily), which also decreases the generation of pro-inflammatory cytokines, autoantibodies, and macrophage infiltration [1]. |
| Animal Protocol |
Animal/Disease Models: 8weeks old C57BL/6 mice were intradermally injected with 2 mg of Freund's complete adjuvant [1]. Doses: 3 mg/kg. Doses: intraperitoneal (ip) injection daily for 2 weeks Experimental Results: Effectively inhibits AIA. Animal/Disease Models: 8weeks old DBA/1J mice were immunized with bovine type II collagen [1]. Doses: 3 mg/kg. Mode of Route of Administration: Daily intraperitoneal (ip) injection. Experimental Results: Effectively inhibited CIA and AIA in mice and diminished the production of pro-inflammatory cytokines and autoantibodies as well as macrophage infiltration. |
| References |
[1]. Suppression of NFAT5-mediated Inflammation and Chronic Arthritis by Novel κB-binding Inhibitors. EBioMedicine. 2017 Apr;18:261-273. |
Solubility Data
| Solubility (In Vitro) |
DMSO : ~18.33 mg/mL (~34.96 mM) H2O : ~1.1 mg/mL (~2.10 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.83 mg/mL (3.49 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 18.3 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.83 mg/mL (3.49 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 18.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.83 mg/mL (3.49 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 18.3 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9070 mL | 9.5351 mL | 19.0701 mL | |
| 5 mM | 0.3814 mL | 1.9070 mL | 3.8140 mL | |
| 10 mM | 0.1907 mL | 0.9535 mL | 1.9070 mL |